UBS Group upgraded CVS Health to Buy from Neutral and raised its 12-month price target to $79 from $67, saying the pharmacy and health-services company is showing "early signs that the Healthcare Benefits segment fixes are on track" after two consecutive quarters of stronger execution. Lead analyst Kevin Caliendo now models a compound annual growth rate of roughly 14% in earnings per share, supported by cost discipline, stabilizing medical costs and CVS’s push into value-based care. The bullish call helped lift CVS shares about 2% to $68.60 in New York trading on Monday, putting the stock on course to break out of a three-year slide highlighted by technical analysts. The UBS note stood out amid a broader wave of Wall Street rating and target changes on the day, with firms also revising views on companies ranging from Chevron to Spotify.